^
    Back
    Association details:
    Biomarker:EGFR amplification
    Cancer:Glioblastoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    T cells and pembrolizumab for recurrent and newly diagnosed glioblastoma

    Excerpt:
    ...Note: Clinical outcome predictors IDH1/2, MGMT status, ATRX, EGFR amplification and Ki-67 not available at screening will be analysed following the completion of recruitment....
    Trial ID:
    ACTRN12623001126606
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancer Immunol Immunother
    Title:

    Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors

    Published date:
    01/28/2023
    Excerpt:
    This was a single-center retrospective study of adult patients diagnosed with first recurrence GBM and received pembrolizumab or nivolumab with or without concurrent bevacizumab....NGS of samples from 15 patients identified EGFR amplification at initial diagnosis and at any time point to be associated with worse survival after ICI (HR 12.2, 95% CI 1.37-108, p = 0.025 and HR 3.92, 95% CI 1.03-14.9, p = 0.045, respectively)…molecular sequencing identified EGFR amplification as associated with worse survival.
    DOI:
    10.1007/s00262-023-03381-y